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γ-SecretaseNeurogenesis impairment starting from early developmental stages is a key determinant of intellectual disability
in Down syndrome (DS). Previous evidence provided a causal relationship between neurogenesis impairment
and malfunctioning of the mitogenic Sonic Hedgehog (Shh) pathway. In particular, excessive levels of AICD
(amyloid precursor protein intracellular domain), a cleavage product of the trisomic gene APP (amyloid precur-
sor protein) up-regulate transcription of Ptch1 (Patched1), the Shh receptor that keeps the pathway repressed.
Since AICD results fromAPP cleavage byγ-secretase, the goal of the current studywas to establishwhether treat-
ment with a γ-secretase inhibitor normalizes AICD levels and restores neurogenesis in trisomic neural precursor
cells. We found that treatment with a selective γ-secretase inhibitor (ELND006; ELN) restores proliferation in
neurospheres derived from the subventricular zone (SVZ) of the Ts65Dn mouse model of DS. This effect was
accompanied by reduction of AICD and Ptch1 levels and was prevented by inhibition of the Shh pathway with
cyclopamine. Treatment of Ts65Dn mice with ELN in the postnatal period P3–P15 restored neurogenesis in the
SVZ and hippocampus, hippocampal granule cell number and synapse development, indicating a positive impact
of treatment on brain development. In addition, in the hippocampus of treated Ts65Dn mice there was a reduc-
tion in the expression levels of various genes that are transcriptionally regulated byAICD, including APP, its origin
substrate. Inhibitors of γ-secretase are currently envisaged as tools for the cure of Alzheimer's disease because
they lower βamyloid levels. Current results provide novel evidence that γ-secretase inhibitors may represent a
strategy for the rescue of neurogenesis defects in DS.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Down syndrome (DS) is a genetic condition caused by the triplica-
tion of human chromosome 21. Intellectual disability is the unavoidable
hallmark of DS, with a heavy impact on public health. In DS patients the
average IQ score is around 50 (range: 30–70) (Creau, 2012; Gardiner,
2015) and in adults with DS it may also be inﬂuenced by the increased
risk of early onset dementia of the Alzheimer's type (Creau, 2012;
Gardiner, 2015; Roizen and Patterson, 2003).
Generalized neurogenesis impairment during critical developmental
stages and impaired dendriticmaturation are themajor determinants ofal and Neuromotor Sciences,
Bologna, BO, Italy.
ghi).
gni contributed equally to this
s Pharmaceuticals, Emeryville,
ect.com).
. This is an open access article underintellectual disability in individuals with DS. Evidence obtained in
mouse models of DS with triplication of different sets of genes or indi-
vidual genes shows that these models may exhibit a similar brain phe-
notype, suggesting that different genes may contribute to the same
brain phenotypic feature. Consistently with this idea, therapeutic ap-
proaches targeted to trisomy-linked alterations of different pathways
can improve/rescue the same brain phenotype (e.g. neurogenesis
alterations).
Accumulating evidence in the Ts65Dn mouse model of DS suggests
that alteration of the Sonic Hedgehog (Shh) pathway may be one im-
portant factor involved in neurogenesis impairment in DS (Roper
et al., 2006; Trazzi et al., 2011, 2013). In particular, defective functioning
of the Shh pathway appears to cause reduced proliferation of neural
precursor cells (NPCs) of the cerebellum (Baxter et al., 2000; Roper
et al., 2006), the subventricular zone (SVZ) of the lateral ventricle
(Trazzi et al., 2011, 2013) and the subgranular zone (SGZ) of the hippo-
campal dentate gyrus (Trazzi et al., 2011). Up-regulation of the Shh
pathway normalizes some developmental defects in Ts65Dn mice
(Dutka et al., 2015). Regarding the causes of Shh signaling impairmentthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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sor protein), a gene that is important for cell cycle progression and
neuronmigration (Nalivaeva and Turner, 2013),may be a key candidate
underlying trisomy-linked alteration of Shh signaling (Trazzi et al.,
2013).
APP undergoes complex proteolytic processing, giving rise to several
fragments. Cleavage of APP by α- and β-secretases gives origin to the
carbossiterminal fragments (CTFs) αCTF and βCTF, respectively. Cleav-
age of αCTF by the enzyme γ-secretase gives origin to the amyloid pre-
cursor protein intracellular domain (AICD) and p3, and cleavage of βCTF
gives origin to βamyloid (Aβ) and AICD. We previously found that ex-
cessive AICD levels in trisomic NPCs caused over-expression of Patched
1 (Ptch1), an Shh receptor that keeps the Shh pathway in a repressed
state (Trazzi et al., 2011, 2013). The outcome of this over-inhibition
was impairment of neurogenesis and neurite development. Treatments
that restored Shh signaling reverted both these defects. In agreement
with a key role played by AICD in neurogenesis alterations in the
Ts65Dnmodel, it has been shown that AICD transgenicmice exhibit im-
paired neurogenesis, similarly to trisomic mice (Ghosal et al., 2010).
The evidence reported above suggests that the impairment of the
Shh pathway that is due to APP-AICD-dependent Ptch1 over-
expression may be a key mechanism that underlies reduced prolifera-
tion and impaired maturation of neuronal precursors in the trisomic
brain. Since Ptch1 over-expression keeps the pathwayunder repression,
therapies have been attempted with SAG, a drug that activates the Shh
pathway by acting downstream of Ptch1 (Das et al., 2013; Roper et al.,
2009). Though this strategy is effective, the use of activators of the
Shh pathwaymay pose some caveats because the Shh pathway is impli-
cated in the development of cancers (Katoh and Katoh, 2009). Since
Ptch1 over-expression in the DS brain is due to excessive AICD levels,
an ideal approach to restore Ptch1 levels and, hence, Shh signaling,
would be to reduce AICD formation through inhibitors of γ-secretase.
During the last few years, various selective APP γ-secretase inhibitors
have been developed (Basi et al., 2010; Fleisher et al., 2008; Probst
et al., 2013) as strategic tools to reduce Aβ levels in Alzheimer's disease.
So far, no study has explored the possibility to exploit γ-secretase inhib-
itors as a pharmacological tool to reduce the excessive levels of AICD
that characterize the DS brain. Reduction of AICD levels is expected to
normalize Ptch1 levels, Shh signaling and, ultimately, neurogenesis.
Based on this rationale, the goal of the current study was to establish
whether treatment with a selective γ-secretase inhibitor positively
impacts neurogenesis in the trisomic brain. To clarify this issue we
have used the Ts65Dn mouse, a widely-used model of DS that exhibits
several features of the human condition. Here we provide evidence
that a selective γ-secretase inhibitor restores Shh signaling in trisomic
neural precursor cells and that this effect leads to restoration of
neurogenesis and hippocampal development.2. Methods
2.1. Colony
Ts65Dn mice were generated by mating B6EiC3Sn a/ATs(17 b 16N)
65Dn females with C57BL/6JEiJ x C3H/HeSnJ (B6EiC3Sn) F1 hybrid
males. This parental generation was provided by Jackson Laboratories
(Bar Harbour, ME, USA). To maintain the original genetic background,
the used mice were the ﬁrst generation of this breeding. Animals were
karyotyped as previously described (Reinholdt et al., 2011). The day of
birth was designated postnatal day zero (P0). A total of 49 mice were
used. The animals' health and comfortwere controlled by the veterinary
service. The animals had access towater and food ad libitumand lived in
a roomwith a 12:12 h dark/light cycle. Experiments were performed in
accordancewith the Italian and European Community law for the use of
experimental animals and were approved by Bologna University
Bioethical Committee (Prot. N.28-IX/9). In this study all efforts weremade to minimize animal suffering and to keep the number of animals
used to a minimum.
2.2. In vitro experiments
2.2.1. Cell cultures
Cellswere isolated from the SVZ of newborn (P2) euploid (n=5) and
Ts65Dn (n = 6) mice and neurosphere cultures were obtained as previ-
ously reported (Trazzi et al., 2011, 2013). Cells were cultured in suspen-
sion in Dulbecco's modiﬁed Eagle's medium (DMEM)/F12 (1:1)
containing B27 supplements (2%), basic ﬁbroblast growth factor (FGF-2,
20 ng/ml), epidermal growth factor (EGF, 20 ng/ml), heparin (5 μg/ml)
and antibiotics (penicillin: 100 units/ml; streptomycin: 100 mg/ml).
Primary neurospheres were dissociated at days 7–8 using Accutase
(PAA, Pasching, Austria) to derive secondary neurospheres. The sub-
culturing protocol consisted of neurosphere passaging every 7 days
with whole culture media change (with freshly added FGF-2 and EGF).
All experiments were done using neurospheres obtained after one to
three passages from the initially prepared cultures. Cell cultures were
kept in a 5% CO2 humidiﬁed atmosphere at 37 °C.
2.2.2. BrdU immunocytochemistry in neurospheres
For proliferation analysis, neurospheres were dissociated in a single
cell suspension and plated onto poly-L-ornithine-coated 24-well cham-
ber slides at a density of 3 × 104 cells per well in a DMEM/F-12medium
containing EGF (20 ng/ml), FGF (20 ng/ml) and 2% FBS. Cells were
treated with ELN 1 nM and, in some experiments, with 10 μg/ml
cyclopamine hydrate (Sigma) for 24 h. Cells were then treated with
BrdU for additional 6 h, paraformaldehyde ﬁxed and stained with a
mouse anti-5-bromo-2-deoxyuridine (BrdU) monoclonal antibody
(1:100; Roche Applied Science) and a Cy3-conjugated anti-mouse
secondary antibody (1:200; Sigma). Samples were counterstained
with Hoechst-33258. Digital images were captured using an Eclipse TE
2000-S microscope and the NIS-Elements AR software (Nikon).
2.2.3. In vitro analysis of differentiation and neurite length of NPCs
Primary neurospheres were dissociated and plated on cover slips
coated with 15 mg/ml poly-L-ornithyine (Sigma). Cells were grown for
2 days in a DMEM/F-12 medium containing EGF (20 ng/ml), FGF
(20 ng/ml), and 2% FBS and then transferred to a differentiatingmedium
(EGF and FGF free plus 1% fetal bovine serum) for 5 days. Every 2 days,
half of themediumwas replenished with fresh differentiatingmedium.
ELN 1 nMwas administered on alternate days throughout the differen-
tiation period (6 days) starting from the ﬁrst day. Differentiated cells
were ﬁxed (see above) and incubated with anti-glial ﬁbrillary acidic
protein (1:400; GFAP mouse monoclonal, Sigma) and anti-β-III tubulin
(1:100; rabbit polyclonal, Sigma), as primary antibodies, and with anti-
mouse FITC-conjugated (1:200; Sigma) and anti-rabbit Cy3-conjugated
(1:200; Jackson Laboratories), as secondary antibodies. Samples were
counterstainedwithHoechst-33258. Cellswere counted inﬁve different
ﬁelds of each cover slip. Number of positive cells for each antibody was
referred to the total number of Hoechst-stained nuclei. Evaluation of
total neurite length of cells differentiated into neurons was performed
by using the image analysis system Image-Pro Plus (Media Cybernetics,
Rockville, MD, USA).
2.2.4. Western blotting
Total proteins were obtained from neurospheres as previously
described (Trazzi et al., 2011). Protein concentration was estimated by
the Lowry method. Proteins (50 μg) were subjected to electrophoresis
on a 4–12% NuPAGE Bis-Tris Precast Gel (Novex, Life Technologies,
Ltd, Paisley, UK) and transferred to a Hybond ECL nitrocellulose
membrane (Amersham Life Science). The following primary antibodies
were used: anti-Amyloid Precursor Protein, C-Terminal (anti-APP;
1:5000; Sigma); anti-Ptch1 rat monoclonal (1:1000; Abcam), anti-
GSK3β mouse mAb (anti-GSK3β; 1:1000; Cell Signaling Technology);
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Cell Signaling Technology); and anti-GAPDH produced in rabbit (anti-
GAPDH; 1:5000; Sigma). For AICD detection, the membrane was proc-
essed for antigen-retrieval as previously described (Trazzi et al., 2011).
Densitometric analysis of digitized imageswas performedwith the soft-
ware Image-Pro Plus and intensity for each band was normalized to the
intensity of the corresponding GAPDH band.
2.3. In vivo experiments
2.3.1. Experimental protocol
During the last few years, various selective APP γ-secretase inhibitors
have beendeveloped by ELAN Inc. (Basi et al., 2010), as strategic tools to re-
duce Aβ levels in Alzheimer's disease. Among these, ELND006 is a γ-
secretase inhibitor which retains selectivity and incorporates improved
drug-like properties (Basi et al., 2010; Probst et al., 2013). Euploid (n =
11) and Ts65Dn (n = 11) mice received a daily subcutaneous injection of
ELND006 (ELN; gift by ELAN Inc, USA) dissolved in 25% PEG300, 25% ethyl-
ene glycol, 25% cremophor, 15% ethanol, 10%propanol frompostnatal day 3
(P3) to postnatal day 15 (P15). Based onprevious evidence,weused a daily
dose of 30mg/kg (Basi et al., 2010; Brighamet al., 2010; Probst et al., 2013).
Age-matchedeuploid (n=8) andTs65Dn(n=8)micewere injectedwith
the vehicle. Each treatment group had approximately the same composi-
tion of males and females. Animals (4–7 animals for each condition) re-
ceived a subcutaneous injection (150 μg/g body weight) of BrdU (5-
bromo-2-deoxyuridine; Sigma), a marker of proliferating cells
(Nowakowski et al., 1989) in Tris HCl 50 mM (at 11–12 am) 2 h before
being euthanized. The brain of the other animals (4 animals for each condi-
tion)was quickly removed, the hippocampal formationwas dissected, kept
at−80 °C and used for western blotting.
2.3.2. Histological procedures
Mice that had received BrdU were deeply anesthetized, the brain
was removed cut along the midline. The left hemisphere was ﬁxed by
immersion in Glyo-Fixx as previously described (Bianchi et al., 2010)
and the right hemispherewasﬁxed in 4% paraformaldehyde and frozen.
The left hemisphere was embedded in parafﬁn and cut in series of 8-
μm-thick coronal sections that were attached to poly-lysine coated
slides and used for BrdU, Ki-67, and cleaved caspase-3 immunohisto-
chemistry and for hematoxylin staining. The right hemisphere was cut
with a freezing microtome in 30-μm-thick coronal sections that were
serially collected in PBS and used for synaptophysin (SYN) and postsyn-
aptic density protein-95 (PSD-95) immunohistochemistry.
2.3.2.1. BrdU immunohistochemistry. One out of 20 sections was taken
from the beginning of the lateral ventricle to the endof thehippocampal
formation (n= 14–18 sections). Sections were processed as previously
described (Bianchi et al., 2010) and incubated overnight at 4 °C with a
primary antibody anti-BrdU (mouse monoclonal 1:100, Roche Applied
Science, Mannheim, Germany). Detection was performed with an
HRP-conjugated anti-mouse secondary antibody (dilution 1:200;
Jackson Immunoresearch, West Grove, PE, USA) and DAB kit (Vector
Laboratories, Burlingame, CA, USA).
2.3.2.2. Ki-67 immunohistochemistry. One out of 20 sections was taken
starting from the beginning of the lateral ventricle up to the end of the
hippocampal formation (n= 16–20 sections). Sections were incubated
overnight at 4 °C with rabbit monoclonal anti-Ki67 antibody (1:100;
Thermo Scientiﬁc). Detection was performed with a HRP-conjugated
anti-rabbit secondary antibody (1:200; Jackson Immunoresearch) and
DAB kit (Vector Laboratories).
2.3.2.3. Cleaved caspase–3 immunohistochemistry. One out of 20 sections
from the beginning of the lateral ventricle to the endof thehippocampal
formation (n = 16–20 sections) was processed for cleaved caspase-3
immunohistochemistry, as previously described (Bianchi et al., 2010).2.3.2.4. SYN and PSD-95 immunohistochemistry. Free-ﬂoating sections
(n = 4–6 per animal) taken at the level of the hippocampal formation
were submitted to ﬂuorescence immunohistochemistry for SYN and
PSD-95. Sections were counterstained with Hoechst dye in order to
label cell nuclei. Sections were incubated for 48 h at 4 °C with mouse
monoclonal anti-SYN (SY38) antibody (Millipore-Biomanufacturing
and Life Science Research, Billerica, MA, USA) or rabbit polyclonal anti-
PSD-95 antibody (Abcam) both diluted 1:1000. Sections were then
incubated overnight at 4 °C with a FITC-conjugated goat anti-mouse
antibody or with a CY3-conjugated anti-rabbit (Jackson Laboratory)
antibody both diluted 1: 200.
2.3.2.5. Hematoxylin-staining. One out of 20 sections, taken from the
beginning to the end of the hippocampal formation (n = 9–12) was
stained with hematoxylin.
2.3.3. Measurements
2.3.3.1. Number of BrdU, Ki-67, and cleaved caspase-3 positive cells. Cells
were sampled from the dentate gyrus (DG) and the rostral
subventricular zone (SVZ). The total number of positive cells in the DG
and SVZ was estimated by multiplying the total number counted in
the series of sampled sections by the inverse of the section sampling
fraction (ssf = 1/20).
2.3.3.2. Synaptic terminals. The intensity of SYN and PSD-95 immuno-
reactivity in the molecular layer of the DG and in the stratum
lucidum of ﬁeld CA3 was determined by the optical densitometry
of immunohistochemically-stained sections. Fluorescence images
were captured using a Nikon Eclipse E600 microscope equipped
with a Nikon Digital Camera DXM1200 (ATI system). Densitometric
analysis of SYN or PSD-95 was carried out using the software Image
Pro Plus as previously described (Guidi et al., 2013). Images
immunoprocessed for SYN or PSD-95 were acquired with a confocal
microscope (Nikon Ti-E ﬂuorescence microscope coupled with an
A1R confocal system, Nikon). In each section three images from the
regions of interest indicated above were captured and the density
of individual puncta exhibiting SYN or PSD-95 immunoreactivity
was evaluated as previously described (Guidi et al., 2013; Stagni
et al., 2013).
2.3.3.3. Stereology of the DG. The volume of the granule cell layer was
evaluated in hematoxylin stained sections. The volume of the granule
cell layer (Vref) was estimated (West and Gundersen, 1990) by multi-
plying the sum of the cross-sectional areas by the spacing T between
sampled sections (T = 160 μm). In the series of sections from the DG
counterstained with the Hoechst dye we evaluated granule cell numer-
ical density using the optical fractionator. Counting frames with a side
length of 30 μm and a height of 8 μm spaced in a 150 μm square grid
(fractionator)were used. Granule cell nuclei intersecting the uppermost
focal plane and intersecting the exclusion lines of the count frame were
not counted. The neuron density (Nv) is given by
NV ¼
X
Q=
X
dis
 
=Vdis
where Q is the number of particles counted in the disectors, dis is the
number of disectors and Vdis is the volume of the disector. The total
number (N) of granule cells was estimated as the product of Vref and
the numerical density (Nv)
N ¼ NV  Vre f :
2.3.4. Western blotting
The samewestern blot analyses carried out in vitro were carried out
in hippocampal homogenates from treated and untreated mice.
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Results are presented as the mean ± SE of the mean. Statistical
testing was performed with ANOVA followed by post hoc comparisons
with Duncan's test. A probability level of p b 0.05 was considered to
be statistically signiﬁcant.3. Results
3.1. Effect of treatment with ELN on proliferation, phenotype acquisition,
and maturation of trisomic NPCs
Neuronal precursor cells (NPCs) from the subventricular zone (SVZ)
of neonate Ts65Dn mice exhibit defects in proliferation rate, neuronal
phenotype acquisition, and maturation (Trazzi et al., 2011, 2013). In
order to establish the effect of γ-secretase inhibition on these defects,
NPCs from the SVZ of Ts65Dn and euploid neonate (P2) mice were
grown as neurospheres and treated with ELN. ELND006 inhibits γ-
secretase mediated cleavage of APP in an in vitro enzyme assay with
an IC50 of 0.3 nM and inhibits Aβ production in cells with an IC50 of
approximately 1 nM. In pilot experimentswe tested the effects of differ-
ent doses of ELN (0.1, 1.0 and 10.0 nM) on neurosphere proliferation.
The lowest dose had no effect on proliferation, the two higher doses in-
creased cell proliferation in a similar manner in trisomic neurospheres,
though in some samples the highest dose induced a smaller increase in
proliferation in comparison with the intermediate dose. Therefore, we
treated cultures with the dose that induced the higher increase in
proliferation rate in trisomic neurospheres (1.0 nM). We found that
while untreated trisomic NPCs exhibited a notably reduced number of
proliferating cells, assessed with BrdU immunohistochemistry, treated
cultures exhibited a number of proliferating cells similar to that of un-
treated euploid cultures (Fig. 1), indicating that treatment had restored
the proliferation defect that characterizes trisomic NPCs. Treatment
with ELN had no effect on proliferation rate in euploid NPCs (Fig. 1).
We next examined the phenotype acquired by untreated and treated
differentiating euploid and trisomic NPCs. Consistently with previous
evidence (Trazzi et al., 2013), untreated trisomic NPCs exhibited a
reduction in the acquisition of a neuronal phenotype, as shown by β-
III tubulin immunoreactivity, and an increase in the acquisition of an as-
trocytic phenotype, as shown by GFAP immunoreactivity (Fig. 2A–D).
After treatment with ELN this defect was fully rescued and in treatedFig. 1. Effect of APP γ-secretase inhibition on proliferation of trisomic neural precursor cells. Ne
inhibitor of APPγ-secretase (ELND006) 1 nM for 24h. Cellswere exposed to BrdU for 6 h in orde
and treated cultures. Nuclei were counterstained with Hoechst staining (blue). Scale bar = 20
centage of untreated euploid NPCs. ** p b 0.01 (Duncan's test after ANOVA). Abbreviations: ELtrisomic NPCs the percentage of new neurons and new astrocytes
became similar to that of untreated euploid NPCs (Fig. 2A–D). Trisomic
NPCs, in addition to proliferation impairment, exhibit defective devel-
opment of neuritic processes (Trazzi et al., 2013). In order to establish
whether treatment positively impacts neurite development, we evalu-
ated the neuritic length of NPCs treatedwith ELN during differentiation.
Treatment with ELN rescued defective neurite development of trisomic
NPCs and total neurite length became similar to that of untreated
euploid NPCs (Fig. 2E, F). Treatment with ELN had no effect on neurite
development in euploid NPCs (Fig. 2E, F).3.2. Effect of treatment with ELN on APP, AICD, Ptch1 and GSK3β protein
expression in trisomic NPCs
Evaluation of APP and AICD levels showed that untreated trisomic
NPCs had higher levels of APP (Fig. 3A, C) andAICD (Fig. 3A, D) in compar-
isonwithuntreated euploidNPCs. In agreementwith the inhibitory action
exerted by ELN on γ-secretase activity, in trisomic NPCs treated with ELN
there was a reduction in AICD levels that became similar to those of eu-
ploid NPCs (Fig. 3A, D). The counterpart of this effect was a parallel in-
crease in the levels of APP CTFs (Fig. 3A). Since in trisomic NPCs high
AICD levels cause an increase in the transcription of Ptch1 (Trazzi et al.,
2011), normalization of AICD levels should lead to a reduction in Ptch1
expression.We found that the abnormally high levels of Ptch1 in trisomic
NPCswere reduced by treatmentwith ELN and became lower in compar-
ison with untreated euploid NPCs (Fig. 3A, E). A reduction in AICD and
Ptch1 levels also took place in treated euploid NPCs (Fig. 3A, D, E).
These ﬁndings indicate that inhibition of APP γ-secretase reinstates the
abnormally high AICD and Ptch1 levels that characterize trisomic NPCs.
GSK3β, a kinase involved in neurogenesis and neuron maturation
(Kim and Snider, 2011), has been shown to have enhanced activity in
the trisomic brain (Trazzi et al., 2014). This kinase becomes active
when dephosphorylated, thereby negatively inﬂuencing proliferation
and differentiation of neural precursor cells. AICD has been shown to
act in the cytoplasmic domain and to reduce the phosphorylation of
GSK3β at Ser9 (Zhou et al., 2012), thereby increasing its activity.
Evaluation of the levels of the phosphorylated form of GSK3β in com-
parison to total GSK3β showed that in untreated trisomic NPCs the
phosphorylated form was reduced in comparison with the euploid
counterparts (Fig. 3B, F). In treated trisomic NPCs there was an increase
in the levels of the phosphorylated form that became similar to those ofural precursor cells (NPCs) from the SVZ of euploid and Ts65Dnmicewere treated with an
r to label proliferating cells. Images show examples of BrdU-labeled cells (red) inuntreated
μm. The histograms show the number (mean ± SE) of proliferating cells expressed as per-
N, ELND006; Eu, euploid.
Fig. 2. Effect of APP γ-secretase inhibition on differentiation of trisomic neural precursor cells. NPCs from the SVZ of euploid and Ts65Dn mice were treated with an inhibitor of APP γ-
secretase (ELND006) 1 nM during differentiation for seven days in culture. A: Examples of differentiated cells expressing the early neuronal marker β-III tubulin (red) and the astrocytic
marker GFAP (green) in untreated and treated cultures. Nuclei were counterstained with Hoechst staining (blue). Scale bar = 20 μm. B–D: Percentage of β-III tubulin-positive cells (B),
GFAP-positive cells (C), and cellswith anundetermined phenotype (D; neither) in untreated and treated cultures. E: Examples of cells expressing the early neuronalmarkerβ-III tubulin in
untreated and treated cultures. Note that euploid cells exhibit longer neuritic processes in comparison with trisomic cells. Nuclei were counterstained with Hoechst staining (blue). Scale
bar = 50 μm. F: Mean length of neurite processes per cell. Histograms in B–D and F are mean ± SE. * p b 0.05; ** p b 0.01; p b 0.001 (Duncan's test after ANOVA). Abbreviations: ELN,
ELND006; Eu, euploid.
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phosphorylation of GSK3β, transcriptionally regulates its expres-
sion (Cao and Sudhof, 2001; Nalivaeva and Turner, 2013; von
Rotz et al., 2004). We found that untreated trisomic NPCs had
higher levels of GSK3β in comparison with the euploid counter-
parts (Fig. 3B, G). In treated trisomic NPCs there was a large reduc-
tion in GSK3β levels that became similar to those of untreated
euploid NPCs (Fig. 3B, G). Unlike in trisomic neurospheres, in eu-
ploid neurospheres treatment did not change levels of phosphory-
lated GSK3β and total GSK3β levels (Fig. 3F, G). However a 13-day-
treatment affected levels of GSK3β and of phosphorylated GSK3β in
euploid mice (see Fig. 8D, E), suggesting that a prolonged treat-
ment is necessary in the euploid condition.
3.3. Inhibition of Shh signaling prevents the pro-neurogenic effect of ELN in
trisomic NPCs
Binding of the Shh peptide to Ptch1 alleviates its inhibition of
Smoothened (Smo), leading to Smo phosphorylation and activation of
the pathway (Zhang et al., 2004). The data reported above suggested
that the positive effect of treatment with ELN on neurogenesis wasdue to normalization of Shh signaling due to restoration of Ptch1 levels
and, hence, disinhibition of Smo. In order to verify this hypothesis, we
treated trisomic and euploid NPCs with ELN and/or cyclopamine, an
inhibitor of Smo. If the effect of ELN on neurogenesis were mediated
by the Shh pathway, inhibition of Smo with cyclopamine should
prevent the effects of ELN on proliferation.
We found that treatment with cyclopamine alone reduced the pro-
liferation rate of euploid NPCs (Fig. 4A). This conﬁrms basal activation
of the Shh pathway in cultures of NPCs due to endogenous production
of Shh (Osterberg and Roussa, 2009; Trazzi et al., 2011). Unlike in
euploid NPCs, in trisomic NPCs cyclopamine had no effect on prolif-
eration rate (Fig. 4A). While in trisomic NPCs treated with ELN
there was an increase in proliferation rate, in trisomic NPCs treated
with ELN plus cyclopamine this increase did not take place and the
proliferation rate remained at the typically low levels of untreated
trisomic NPCs (Fig. 4A). The ﬁnding that in trisomic NPCs treatment
normalizes Ptch1 levels (Fig. 3A,E) and that inhibition of the Shh
pathway through cyclopamine prevents restoration of prolifera-
tion (Fig. 4A) strongly suggests that the increase in proliferation
rate induced by treatment with ELN is mediated through the Shh
pathway.
Fig. 3. Effect of APP γ-secretase inhibition on APP, AICD, Ptch1 and GSK3β protein expression in trisomic NPCs. Neural precursor cells (NPCs) from the SVZ of euploid and Ts65Dn mice,
grown as neurospheres,were treatedwith an inhibitor of APP γ-secretase (ELND006) 1 nM for 24 h. A, B:Western blot analysis of Ptch1, APP, CTFs, AICD andGAPDH (A) and p-GSK3β and
GSK3β (B) in neurospheres from untreated and treated euploid and Ts65Dnmice. The empty and ﬁlled arrows in (A) indicate the CTFs and AICD band, respectively. Note the low levels of
AICD in comparison with the high levels of the CTFs.Western blots in (B) are from the same brain samples as in (A). C–G: The histograms (mean± SE) show APP (C), AICD (D), Ptch1 (E),
pGSK3β (F) andGSK3β (G) levels expressed as fold difference in comparisonwith untreated euploidNPCs. Data in (C–E, G)were normalized to GAPDHand data in (F)were normalized to
total GSK3β. Western blot images are explicative reconstructions. * p b 0.05; ** p b 0.01; *** p b 0.001 (Duncan's test after ANOVA). Abbreviations: ELN, ELND006; Eu, euploid.
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SGZ of Ts65Dn mice
Results obtained in vitro suggested that treatmentwith ELNmight be
used for correcting the neurogenesis defects that characterize DS. There-
fore, we treated Ts65Dn (and euploid)micewith ELN frompostnatal day
3 to postnatal day 15, in order to establishwhether treatmentwas able to
restore neurogenesis in vivo. At postnatal day 15 mice were injected
with BrdU, a marker of the S-phase of the cell cycle, and were killed
after 2 h. Evaluation of the number of proliferating cells in SGZ of the
dentate gyrus (DG) and in the SVZ of the lateral ventricle showed that,
consistently with previous evidence (Bianchi et al., 2010), Ts65Dn mice
had fewer BrdU+ cells in comparison with euploid mice (Fig. 5A–D).
Treatment with ELN increased the number of BrdU+ cells in Ts65Dn
mice, so that treated mice had a similar number of BrdU+ cells as un-
treated euploid mice both in the DG (Fig. 5C) and SVZ (Fig. 5D). A com-
parison between treated and untreated euploidmice showed no effect of
treatment (Fig. 5C,D). To establish whether treatment with ELN restores
the overall size of the population of neural precursors in the DG and SVZ
of Ts65Dn mice, we evaluated the number of cells immunopositive for
Ki-67, an endogenous marker expressed during phases G1, S, G2 and M
of the cell cycle (Scholzen and Gerdes, 2000). We found that in the DG
of untreated Ts65Dnmice there were fewer Ki-67+ cells in comparison
with euploid mice (Fig. 5E). In treated Ts65Dn mice the number ofcycling cells underwent an increase and became similar to that of euploid
mice (Fig. 5E). Similar ﬁndings were obtained in the SVZ (Fig. 5F). The
protein cleaved caspase-3 is one of the hallmarks of apoptotic death
(Blomgren et al., 2007). Evaluation of the number of cells expressing
cleaved caspase-3 showed that untreated Ts65Dn mice had a similar
number of apoptotic cells as untreated euploid mice both in the DG
and SVZ and that the number of apoptotic cells was not affected by treat-
ment both in euploid and Ts65Dnmice (Fig. 5G,H). Taken together, these
results indicate that treatment with ELN during the ﬁrst two postnatal
weeks restores the number of neural precursor cells in the DG and SVZ
of Ts65Dn mice and suggest that this effect is due to an increase in
proliferation potency and not to a decrease in cell death.
3.5. Effect of neonatal treatment with ELN on granule cell number in the
dentate gyrus of Ts65Dn mice
Inmice, the SGZ producesmost of the granule cells that populate the
granule cell layer of theDG in the ﬁrst two postnatalweeks (Altman and
Bayer, 1975). Hypocellularity in the dentate gyrus of Ts65Dn mice due
to proliferation impairment has been documented starting from neona-
tal life stages (Guidi et al., 2014; Lorenzi and Reeves, 2006). In order to
establish whether the increase in the number of neural cell precursors
in the DG of treated Ts65Dn mice (Fig. 5) translated into restoration of
total granule cell number, we evaluated the number of granule cells at
Fig. 4. Inhibition of the Shh pathway prevents the effects of ELN on proliferation. Neural
precursor cells (NPCs) from the SVZ of euploid (EU) and Ts65Dn mice, grown as
neurospheres, were treated with an inhibitor of APP γ-secretase (ELND006; ELN) 1 nM,
cyclopamine (CYC) 10 μg/ml, and ELN plus cyclopamine for 24 h. Cells were exposed to
BrdU for 6 h in order to label proliferating cells. The histogram shows the number
(mean ± SE) of proliferating cells expressed as percentage of untreated euploid NPCs.
The asterisks indicate a difference in comparison with untreated euploid neurospheres.
The symbol # indicates a difference in comparison with untreated trisomic neurospheres.
* p b 0.05; ** p b 0.01; # p b 0.05 (Duncan's test after ANOVA).
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volume of the granule cell layer, granule cell density and total granule
cell number (Fig. 6). In contrast, in Ts65Dnmice, treatment signiﬁcantly
increased the volume of the granule cell layer, granule cell density and
total granule cell number (Fig. 6). A comparison between treated
Ts65Dn and untreated euploid mice showed no differences (Fig. 6),
indicating a treatment-induced rescue in the development of the
granule cell layer.
3.6. Effect of neonatal treatment with ELN on hippocampal synapse
development
In view of restoration of total granule cell number in treated Ts65Dn
micewewonderedwhether this effect was accompanied by restoration
of synapse development, a process that is impaired in the trisomic brain
(Belichenko et al., 2007; Chakrabarti et al., 2007; Guidi et al., 2013; Kurt
et al., 2004). To this purpose, in hippocampal sections from treated and
untreated mice we evaluated the immunoreactivity for synaptophysin
(SYN), a marker of presynaptic terminals, and the postsynaptic density
protein-95 (PSD-95), a marker of postsynaptic sites. We focused on the
molecular layer of the DG because this layer receives themajor input to
the hippocampus, the perforant pathway, and the stratum lucidum of
ﬁeld CA3, the site of termination of the axons of the granule cells
(Amaral and Witter, 1995).
Results showed that in untreated Ts65Dn mice the immunoreactiv-
ity for SYN was signiﬁcantly lower than in untreated euploid mice in
the inner (−21%), middle (−16%) and outer (−15%) molecular layer
of the DG (Fig. 7A, B) and in the stratum lucidum (−13%) of CA3
(Fig. 7A, C). In parallel with the reduction of SYN immunoreactivity, in
Ts65Dn mice there was a reduction in the immunoreactivity for PSD-
95 in the inner (−10%), middle (−15%) and outer (−8%) molecular
layer of the DG (Fig. 7G, H) and in the stratum lucidum (−10%) of
CA3 (Fig. 7G,I). In treated Ts65Dn mice, in all zones of the molecular
layer and in the stratum lucidum of CA3 there was an increase in the
immunoreactivity for SYN (Fig. 7A, B, C) and PSD-95 (Fig. 7G, H, I) that
became similar to that of untreated euploid mice. In euploid mice,
treatment did not affect the immunoreactivity for SYN (Fig. 7A, B, C)
and PSD-95 (Fig. 7G, H, I) both in the DG and CA3. In order to establish
whether the effects of genotype and treatment on protein levels were
attributable to different levels of synaptic proteins per synapse or to
differences in the number of synapses, we evaluated the density of indi-
vidual puncta exhibiting either SYN or PSD-95 immunoreactivity.While
untreated Ts65Dn mice had fewer puncta exhibiting immunoreactivityfor SYN (Fig. 7D, E, F) and PSD-95 (Fig. 7J, K, L) both in the DG and
CA3, neonatally-treated Ts65Dn mice had a similar number of SYN
(Fig. 7D, E, F) and PSD-95 (Fig. 7J, K, L) puncta as untreated euploid
mice in both regions, suggesting that treatment had restored hippocam-
pal synapse development.
3.7. Effect of neonatal treatment with ELN on AICD targets in the
hippocampus of Ts65Dn mice
Evaluation of Ptch1 expression levels showed that while untreated
Ts65Dn mice had higher Ptch1 levels in comparison with euploid
mice, after treatment with ELN the levels of Ptch1 underwent a large
decrease. A reduction in Ptch1 levels also took place in treated in com-
parison with untreated euploid mice (Fig. 8A, B). AICD has been
shown to transcriptionally up-regulate APP itself (Cao and Sudhof,
2001; Nalivaeva and Turner, 2013; von Rotz et al., 2004).While untreat-
ed Ts65Dn mice had notably higher levels of APP in comparison with
euploid mice (Fig. 8A, C), in treated Ts65Dnmice APP levels underwent
a large reduction in comparison with their untreated counterparts,
though they remained larger in comparison with untreated euploid
mice (Fig. 8A, C). Treatment had no effect on APP levels in euploid
mice (Fig. 8A, C). While in untreated Ts65Dn mice the levels of phos-
phorylated GSK3β were reduced in comparison with euploid mice
(Fig. 8A, D), in treated mice the levels of phosphorylated GSK3β
underwent an increase and became even higher than those of untreated
euploid mice (Fig. 8A, D). An increase also took place in treated in
comparison with untreated euploid mice (Fig. 8A, D). Evaluation of
the expression levels of GSK3β showed that while untreated Ts65Dn
mice had higher levels of GSK3β in comparison with euploid mice
(Fig. 8A, E), in treated Ts65Dn mice GSK3β levels underwent a large
reduction (Fig. 8A, E). A reduction in GSK3β levels also took place in
treated in comparison with untreated euploid mice (Fig. 8A, E).
4. Discussion
4.1. Treatment with a γ-secretase inhibitor restores neurogenesis in
trisomic NPCs by disinhibiting the Shh pathway
Among the triplicated genes, some located inside and outside the
Down syndrome critical region have been reported as likely candidates
involved in the neurogenesis impairment that characterizes this genetic
condition (Costa and Scott-McKean, 2013; Dierssen, 2012). Previous
(Trazzi et al., 2011, 2013) and current results highlight the contribution
of the triplicated gene APP in neurogenesis impairment in DS. APP
triplication causes excessive formation of AICD which, in turn, causes
excessive transcription of various genes, including Ptch1, the Shh recep-
tor that inhibits the Shh pathway. This pathway is strongly involved in
neural precursor cell proliferation, migration and differentiation
(Angot et al., 2008; Machold et al., 2003). We found that treatment
with ELN reduced AICD and Ptch1 levels in trisomic NPCs and that this
effectwas accompanied by neurogenesis restoration. In order to provide
a causal link between neurogenesis restoration in trisomic NPCs and the
Shh pathway, we used cyclopamine, an inhibitor of Smo.We found that
the reduced proliferation rate of trisomic NPCs was not further reduced
by cyclopamine alone, suggesting saturation of the inhibition exerted by
Ptch1 on Smo.While treatmentwith ELN restored proliferation of triso-
mic NPCs, this effect was prevented if the Shh pathway was pharmaco-
logically repressed through cyclopamine. This clearly indicates the
involvement of the Shh pathway in the pro-neurogenic effect exerted
by treatment. In euploid NPCs cyclopamine alone moderately reduced
neurogenesis indicating that the Shh pathway contributes to ongoing
neurogenesis under basal conditions. In euploid NPCs ELN did not
further increase proliferation, suggesting that reduction of AICD/
Ptch1 at levels lower than those normally present in euploid NPCs
cannot further enhance the activity of the Shh pathway.
Fig. 5. Effect of APPγ-secretase inhibition on proliferation potency in the dentate gyrus and subventricular zone of Ts65Dn and euploidmice. Animals received a daily injection of ELND006
or vehicle in the period P3–P15. On P15 they received one injection of BrdU andwere sacriﬁced after 2 h. A–B: Sections immunostained for BrdU from theDG (A) and SVZ (B) of untreated
and treated euploid and Ts65Dnmice. Scale bar: 100 μm(A); 50 μm(B). C, D: Total number of BrdU-positive cells in the DG (C) and SVZ (D) of untreated euploid (n=5) and Ts65Dn (n=
4)mice and euploid (n=4) and Ts65Dn (n=5)mice treatedwith ELN. E, F: Number of Ki-67 positive cells in the dentate gyrus (E) and SVZ (F) of untreated euploid (n= 5) and Ts65Dn
(n = 4) mice and euploid (n = 4) and Ts65Dn (n = 5) mice treated with ELN. Number of cleaved caspase-3 positive cells in the DG (E) and SVZ (F) of untreated euploid (n = 5) and
Ts65Dn (n = 4) mice and euploid (n = 4) and Ts65Dn (n = 5) mice treated with ELN. Values (mean ± SE) in (C–H) represent totals for one hemisphere. * p b 0.05; ** p b 0.01;
*** p b 0.001 (Duncan's test after ANOVA). Abbreviations: DG, dentate gyrus; ELN, ELND006; Eu, euploid; LV, lateral ventricle; SVZ, subventricular zone.
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in the major postnatal neurogenic niches
Results obtained in vitro were suggestive of a potential impact of
treatment with ΕLΝ (or other selective APP γ-secretase inhibitors) as
a therapeutic tool for correcting neurogenesis impairment and
hypocellularity in the trisomic brain. Since the hippocampal dentate
gyrus mainly develops in the early postnatal period in rodents, we
decided to treat neonate mice with ELN during the ﬁrst two postnatal
weeks in order to impact hippocampal development. We found that
the typically reduced number of neural precursors in the dentate
gyrus of Ts65Dn mice was fully normalized at the end of treatment. Asimilar result was obtained in the SVZ, indicating that treatment
positively impacts neurogenic niches located in different brain parts.
Treatment did not affect cell death in either neurogenic region, suggest-
ing that there was no adverse effect of treatment on cell survival. Since
the bulk of granule neurons is generated during the ﬁrst 7–10 postnatal
days (Altman and Bayer, 1975), we hypothesized that the outcome of
neurogenesis restoration in Ts65Dn mice may be an increase in the
cellularity of the dentate gyrus. Consistently with this idea, in treated
Ts65Dn mice the volume of the granule cell layer and total granule
cell number became similar to those of euploid mice, indicating that
treatment with ELN leads to normalization of hippocampal cellularity.
In euploid mice, neonatal treatment with ELN had no effect on
Fig. 6. Effect of APP γ-secretase inhibition on total granule cell number in the dentate gyrus. A: Hoechst-stained coronal section across the dentate gyrus of an animal of each experimental
group. The higher magniﬁcation images in the lower row correspond to the region enclosed in the dotted box in the upper row. Scale bar = 50 μm (upper row); 10 μm (lower row). B:
Volume of the granule cell layer, density of granule cells (number permm3) and total number of granule cells of theDG. Values aremean±SE. Volumeand granule cell number refer to one
hemisphere. * p b 0.05; ** p b 0.01; *** p b 0.001 (Duncan's test after ANOVA). Abbreviations: ELN, ELND006; Eu, euploid; GR, granule cell layer; MOL, molecular layer.
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levels (see Fig. 8A, B). This suggests that in the normal brain the Shh
pathway is optimally active under basal conditions and that a further
disinhibition does not increase its efﬁcacy.
A reduced number of pre- and postsynaptic terminals has been doc-
umented in various brain regions, including the molecular layer of the
DG, of trisomic mice (Belichenko et al., 2007; Chakrabarti et al., 2007;
Guidi et al., 2013; Kurt et al., 2004). Therefore, the trisomy-dependent
defective functioning of hippocampal circuits appears to be due not
only to a reduced number of neurons populating this structure, but
also to input–output alterations. The major hippocampal input derives
from the entorhinal cortex. Signals then progress to the DG and, conse-
quently, are transferred to ﬁeld CA3 and then CA1. Signals processed
along this circuit are essential for hippocampus-dependent long-term
memory functions. We found that treatment restored the number of
pre- and postsynaptic terminals in the molecular layer of the DG,
suggesting restoration of the major input to the DG. In view of the
increase in total granule cell number we sought to establish whether
the counterpart of this effect was an increase in the number of pre-
and postsynaptic terminals in the stratum lucidum of CA3, the site of
termination of the axons of the granule cells. Treated trisomic mice
exhibited full restoration of pre- and postsynaptic terminals, suggesting
restoration of signal transfer to CA3. Synapse and dendrite development
are modulated by various molecular mechanisms, amongwhich GSK3β
appears to be a key player. Dephosphorylation of GSK3β leads to
marked shrinkage of dendrites, whereas its inhibition (phosphoryla-
tion) enhances dendritic growth and GSK3β phosphorylation is
required for proper synapse development (Jin et al., 2012; Kim and
Snider, 2011; Rui et al., 2013). The ﬁnding that treatment with ELNincreased GSK3β phosphorylation in Ts65Dn mice suggests that this
effect may contribute to the restoration of neurite length, observed
here in cultures on NPCs, and synapse development, observed in vivo.
4.3. Neonatal treatment with a γ-secretase inhibitor impacts APP
processing in Ts65Dn mice
While a 24 h treatment with ELN did not change APP levels in
trisomic NPCs (see Fig. 3C), in mice treated for 13 days there was a
reduction in APP levels (see Fig. 8A, C). Since AICD promotes transcrip-
tion of APP itself, the reduction of APP levels in mice treated with ELN
may be attributable to a reduction in the AICD-mediated transcription
of APP. It has been shown that inhibition of GSK3 decreases APP levels
by enhancing its degradation via an increase in the number of lyso-
somes (Parr et al., 2012). In treatedmice therewas increased phosphor-
ylation (i.e., increased inhibition) of GSK3β. Therefore, the reduction of
APP levels in treated Ts65Dnmicemay also be due to an increase in APP
degradation. Since APP acts to markedly decrease NGF retrograde
transport and cause degeneration of BFCNs (Salehi et al., 2006), the
treatment induced reduction in APP levels may prevent cholinergic
neurodegeneration.
4.4. Conclusions
Results show that inhibition of APP γ-secretase restores neuro-
genesis, hippocampal granule cell number and synaptic development
in a mouse model of DS. We used a selective inhibitor of APP γ-
secretase (ELND006) that was created in order to reduce Aβ formation
in Alzheimer's disease (Basi et al., 2010; Probst et al., 2013). Our results
Fig. 7. Effect of APP γ-secretase inhibition on synapse development in the hippocampal formation. A, G: Sections processed for SYN (A) and PSD-95 (G) immunoﬂuorescence from the DG
(upper row) and CA3 (lower row) of an animal from each experimental group. Scale bar=100 μm. B, C, H, I: Optical density of SYN (B, C) and PSD-95 (H, I) immunoreactivity in the inner,
middle and outer third of themolecular layer of theDG (B,H) and the stratum lucidumof CA3 (C, I) of untreated euploid (n=6) and Ts65Dn (n=5)mice and euploid (n=6) and Ts65Dn
(n=5)mice treatedwith ELND006. For each region, data of SYN and PSD-95 immunoreactivity are given as fold difference vs. untreated euploidmice. D, J: Images, takenwith the confocal
microscope, of sections processed for SYN (D) and PSD-95 (J) immunoﬂuorescence from theDGof an animal of each experimental group. Scale bar=3 μm. E, F, K, L: Number of puncta per
μm2 exhibiting SYN (E, F) and PSD-95 (K, L) immunoreactivity in the inner,middle and outer third of themolecular layer of theDG (E, K) and the stratum lucidumof CA3 (F, L) of untreated
euploid (n = 6), untreated Ts65Dn (n = 5), and euploid (n = 6) and Ts65Dn (n = 5) mice treated with ELND006. Values in B, C, E, F, F, H, I, K and L represent mean ± SE. * p b 0.05;
** p b 0.01; *** p b 0.001 (Duncan's test after ANOVA). Abbreviations: ELN, ELND006; Eu, euploid; GR, granule cell layer; i, inner; LUC, stratum lucidum; m, middle; MOL, molecular
layer; o, outer.
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improve neurogenesis defects in DS through a reduction in AICD forma-
tion. Indeed, early treatment with ELND006 restored neurogenesis in
the two major neurogenic niches of the postnatal brain and develop-
ment of the hippocampal dentate gyrus. ELND006 was developed as
an APP selective γ-secretase inhibitor for the treatment of AD, and stud-
ies have shown that ELND006, at therapeutic doses, has no toxic effects
on wild-type mice and nonhuman primates (Basi et al., 2010; Brighamet al., 2010), but a clinical trial with ELND006 in elderly healthy volun-
teers was discontinued due to elevation of liver enzyme levels, a sign
of liver toxicity (Hopkins, 2011). Yet, though ELND006 by itself may
not be a suitable drug for DS (or AD), our study provides novel demon-
stration that inhibitors of γ-secretase can completely reinstate
neurogenesis in the trisomic brain. Intense research is being carried
out in order to devise safe inhibitors of γ-secretase for the cure of
Alzheimer's disease. For instance, a modulator of γ-secretase as well
Fig. 8. Effect of APP γ-secretase inhibition on AICD targets. A: Western blot analysis of
Ptch1, APP, phosphorylated GSK3β and total GSK3β in the hippocampus of Ts65Dn and
euploid mice. B-E: Ptch1 (B), APP (C), pGSK3β (D) and total GSK3β (E) levels. Data in B,
C and E were normalized to GAPDH and data in (D) were normalized to total GSK3β.
Values in (B–E) (mean± SE) are expressed as fold difference in comparisonwith untreat-
ed euploid mice. All western blot images are explicative reconstructions. (*) p b 0.06;
* p b 0.05; ** p b 0.01; *** p b 0.001 (Duncan's test after ANOVA). Abbreviations: ELN,
ELND006; Eu, euploid.
395A. Giacomini et al. / Neurobiology of Disease 82 (2015) 385–396as direct inhibitor of AICD activity has recently been developed (Branca
et al., 2014). All this evidence prospects that there will soon be the
possibility to exploit safe drugs in order to reduce AICD levels/activity
and correct the neurogenesis defects of DS.
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